Abstract |
Betulinic acid (BA) and betulin (BE) are naturally pentacyclic triterpenes with documented biological activities, especially antitumor and anti-inflammatory activity. However, their bioavailability in vivo is not satisfactory in terms of medical applications. Thus, to improve the solubility and bioavailability so as to improve the efficacy, 28-O-succinyl betulin (SBE), a succinyl derivative of BE, was synthesized and its solubility, in vitro and in vivo anti- tumor activities, the apoptosis pathway as well as the pharmacokinetic properties were investigated. The results showed that SBE exhibited significantly higher solubility in most of the tested solvents, and showed a maximum solubility of 7.19 ± 0.66 g/L in n-butanol. In vitro and in vivo anti- tumor activity assays indicated both BA and SBE exhibited good anti- tumor activities, and SBE demonstrated better potential compared to BA. An increase in the ratio of Bad/Bcl-xL and activation of caspase 9 was found in SBE treated Hela cells, suggesting that the intrinsic mitochondrial pathway is involved in SBE induced apoptosis. Compared with BA, SBE showed much-improved absorption and bioavailability in pharmacokinetic studies.
|
Authors | Yucen Liang, Meixuan Zhu, Tao Xu, Weimin Ding, Min Chen, Yang Wang, Jian Zheng |
Journal | Molecules (Basel, Switzerland)
(Molecules)
Vol. 28
Issue 15
(Jul 28 2023)
ISSN: 1420-3049 [Electronic] Switzerland |
PMID | 37570685
(Publication Type: Journal Article)
|
Chemical References |
- betulin
- Betulinic Acid
- Triterpenes
- Pentacyclic Triterpenes
|
Topics |
- Humans
- Rats
- Animals
- Betulinic Acid
- HeLa Cells
- Solubility
- Triterpenes
(pharmacology)
- Pentacyclic Triterpenes
- Cell Line, Tumor
|